Second-line treatment for failure to eradicate Helicobacter pylori: a randomized trial comparing four treatment strategies
Lamouliatte, H. ; Mégraud, F. ; Delchier, J.-C. ; Bretagne, J.-F. ; Courillon-Mallet, A. ; De Korwin, J.-D. ; Fauchère, J.-L. ; Labigne, A. ; Fléjou, J.-F. ; Barthelemy, P.
Oxford, UK : Blackwell Science Ltd
Published 2003
Oxford, UK : Blackwell Science Ltd
Published 2003
| ISSN: |
1365-2036
|
|---|---|
| Source: |
Blackwell Publishing Journal Backfiles 1879-2005
|
| Topics: |
Medicine
|
| Notes: |
Aim : To compare the efficacy of different regimens in patients in whom previous Helicobacter pylori eradication therapy has failed.Methods : In this study named StratHegy patients (n = 287) were randomized to receive one of three empirical triple therapy regimens or a strategy based on antibiotic susceptibility. The empirical regimens were omeprazole, 20 mg b.d., plus amoxicillin, 1000 mg b.d., and clarithromycin, 500 mg b.d., for 7 days (OAC7), clarithromycin, 500 mg b.d., for 14 days (OAC14) or metronidazole, 500 mg b.d., for 14 days (OAM14). In the susceptibility-based strategy, patients with clarithromycin-susceptible strains received OAC14, whilst the others received OAM14. The 13C-urea breath test was performed before randomization and 4–5 weeks after eradication therapy.Results : In the intention-to-treat analysis, the eradication rates for empirical therapies were as follows: OAC7, 47.4% (27/57); OAC14, 34.5% (20/58); OAM14, 63.2% (36/57); it was 74.3% (84/113) for the susceptibility-based treatment (P 〈 0.01 when compared with OAC7 and OAC14). In patients receiving clarithromycin, the eradication rates were 80% for clarithromycin-susceptible strains and 16% for clarithromycin-resistant strains; in patients receiving OAM14, the eradication rates were 81% for metronidazole-susceptible strains and 59% for metronidazole-resistant strains.Conclusions : Eradication rates of approximately 75% can be achieved with second-line triple therapy based on antibiotic susceptibility testing. If susceptibility testing is not available, OAM14 is an appropriate alternative.
|
| Type of Medium: |
Electronic Resource
|
| URL: |
| _version_ | 1798290074090078208 |
|---|---|
| autor | Lamouliatte, H. Mégraud, F. Delchier, J.-C. Bretagne, J.-F. Courillon-Mallet, A. De Korwin, J.-D. Fauchère, J.-L. Labigne, A. Fléjou, J.-F. Barthelemy, P. |
| autorsonst | Lamouliatte, H. Mégraud, F. Delchier, J.-C. Bretagne, J.-F. Courillon-Mallet, A. De Korwin, J.-D. Fauchère, J.-L. Labigne, A. Fléjou, J.-F. Barthelemy, P. |
| book_url | http://dx.doi.org/10.1046/j.1365-2036.2003.01759.x |
| datenlieferant | nat_lic_papers |
| hauptsatz | hsatz_simple |
| identnr | NLZ242200826 |
| insertion_date | 2012-04-27 |
| issn | 1365-2036 |
| journal_name | Alimentary pharmacology & therapeutics |
| materialart | 1 |
| notes | Aim : To compare the efficacy of different regimens in patients in whom previous Helicobacter pylori eradication therapy has failed.Methods : In this study named StratHegy patients (n = 287) were randomized to receive one of three empirical triple therapy regimens or a strategy based on antibiotic susceptibility. The empirical regimens were omeprazole, 20 mg b.d., plus amoxicillin, 1000 mg b.d., and clarithromycin, 500 mg b.d., for 7 days (OAC7), clarithromycin, 500 mg b.d., for 14 days (OAC14) or metronidazole, 500 mg b.d., for 14 days (OAM14). In the susceptibility-based strategy, patients with clarithromycin-susceptible strains received OAC14, whilst the others received OAM14. The 13C-urea breath test was performed before randomization and 4–5 weeks after eradication therapy.Results : In the intention-to-treat analysis, the eradication rates for empirical therapies were as follows: OAC7, 47.4% (27/57); OAC14, 34.5% (20/58); OAM14, 63.2% (36/57); it was 74.3% (84/113) for the susceptibility-based treatment (P 〈 0.01 when compared with OAC7 and OAC14). In patients receiving clarithromycin, the eradication rates were 80% for clarithromycin-susceptible strains and 16% for clarithromycin-resistant strains; in patients receiving OAM14, the eradication rates were 81% for metronidazole-susceptible strains and 59% for metronidazole-resistant strains.Conclusions : Eradication rates of approximately 75% can be achieved with second-line triple therapy based on antibiotic susceptibility testing. If susceptibility testing is not available, OAM14 is an appropriate alternative. |
| package_name | Blackwell Publishing |
| publikationsjahr_anzeige | 2003 |
| publikationsjahr_facette | 2003 |
| publikationsjahr_intervall | 7999:2000-2004 |
| publikationsjahr_sort | 2003 |
| publikationsort | Oxford, UK |
| publisher | Blackwell Science Ltd |
| reference | 18 (2003), S. 0 |
| search_space | articles |
| shingle_author_1 | Lamouliatte, H. Mégraud, F. Delchier, J.-C. Bretagne, J.-F. Courillon-Mallet, A. De Korwin, J.-D. Fauchère, J.-L. Labigne, A. Fléjou, J.-F. Barthelemy, P. |
| shingle_author_2 | Lamouliatte, H. Mégraud, F. Delchier, J.-C. Bretagne, J.-F. Courillon-Mallet, A. De Korwin, J.-D. Fauchère, J.-L. Labigne, A. Fléjou, J.-F. Barthelemy, P. |
| shingle_author_3 | Lamouliatte, H. Mégraud, F. Delchier, J.-C. Bretagne, J.-F. Courillon-Mallet, A. De Korwin, J.-D. Fauchère, J.-L. Labigne, A. Fléjou, J.-F. Barthelemy, P. |
| shingle_author_4 | Lamouliatte, H. Mégraud, F. Delchier, J.-C. Bretagne, J.-F. Courillon-Mallet, A. De Korwin, J.-D. Fauchère, J.-L. Labigne, A. Fléjou, J.-F. Barthelemy, P. |
| shingle_catch_all_1 | Lamouliatte, H. Mégraud, F. Delchier, J.-C. Bretagne, J.-F. Courillon-Mallet, A. De Korwin, J.-D. Fauchère, J.-L. Labigne, A. Fléjou, J.-F. Barthelemy, P. Second-line treatment for failure to eradicate Helicobacter pylori: a randomized trial comparing four treatment strategies Blackwell Science Ltd Aim : To compare the efficacy of different regimens in patients in whom previous Helicobacter pylori eradication therapy has failed.Methods : In this study named StratHegy patients (n = 287) were randomized to receive one of three empirical triple therapy regimens or a strategy based on antibiotic susceptibility. The empirical regimens were omeprazole, 20 mg b.d., plus amoxicillin, 1000 mg b.d., and clarithromycin, 500 mg b.d., for 7 days (OAC7), clarithromycin, 500 mg b.d., for 14 days (OAC14) or metronidazole, 500 mg b.d., for 14 days (OAM14). In the susceptibility-based strategy, patients with clarithromycin-susceptible strains received OAC14, whilst the others received OAM14. The 13C-urea breath test was performed before randomization and 4–5 weeks after eradication therapy.Results : In the intention-to-treat analysis, the eradication rates for empirical therapies were as follows: OAC7, 47.4% (27/57); OAC14, 34.5% (20/58); OAM14, 63.2% (36/57); it was 74.3% (84/113) for the susceptibility-based treatment (P 〈 0.01 when compared with OAC7 and OAC14). In patients receiving clarithromycin, the eradication rates were 80% for clarithromycin-susceptible strains and 16% for clarithromycin-resistant strains; in patients receiving OAM14, the eradication rates were 81% for metronidazole-susceptible strains and 59% for metronidazole-resistant strains.Conclusions : Eradication rates of approximately 75% can be achieved with second-line triple therapy based on antibiotic susceptibility testing. If susceptibility testing is not available, OAM14 is an appropriate alternative. 1365-2036 13652036 |
| shingle_catch_all_2 | Lamouliatte, H. Mégraud, F. Delchier, J.-C. Bretagne, J.-F. Courillon-Mallet, A. De Korwin, J.-D. Fauchère, J.-L. Labigne, A. Fléjou, J.-F. Barthelemy, P. Second-line treatment for failure to eradicate Helicobacter pylori: a randomized trial comparing four treatment strategies Blackwell Science Ltd Aim : To compare the efficacy of different regimens in patients in whom previous Helicobacter pylori eradication therapy has failed.Methods : In this study named StratHegy patients (n = 287) were randomized to receive one of three empirical triple therapy regimens or a strategy based on antibiotic susceptibility. The empirical regimens were omeprazole, 20 mg b.d., plus amoxicillin, 1000 mg b.d., and clarithromycin, 500 mg b.d., for 7 days (OAC7), clarithromycin, 500 mg b.d., for 14 days (OAC14) or metronidazole, 500 mg b.d., for 14 days (OAM14). In the susceptibility-based strategy, patients with clarithromycin-susceptible strains received OAC14, whilst the others received OAM14. The 13C-urea breath test was performed before randomization and 4–5 weeks after eradication therapy.Results : In the intention-to-treat analysis, the eradication rates for empirical therapies were as follows: OAC7, 47.4% (27/57); OAC14, 34.5% (20/58); OAM14, 63.2% (36/57); it was 74.3% (84/113) for the susceptibility-based treatment (P 〈 0.01 when compared with OAC7 and OAC14). In patients receiving clarithromycin, the eradication rates were 80% for clarithromycin-susceptible strains and 16% for clarithromycin-resistant strains; in patients receiving OAM14, the eradication rates were 81% for metronidazole-susceptible strains and 59% for metronidazole-resistant strains.Conclusions : Eradication rates of approximately 75% can be achieved with second-line triple therapy based on antibiotic susceptibility testing. If susceptibility testing is not available, OAM14 is an appropriate alternative. 1365-2036 13652036 |
| shingle_catch_all_3 | Lamouliatte, H. Mégraud, F. Delchier, J.-C. Bretagne, J.-F. Courillon-Mallet, A. De Korwin, J.-D. Fauchère, J.-L. Labigne, A. Fléjou, J.-F. Barthelemy, P. Second-line treatment for failure to eradicate Helicobacter pylori: a randomized trial comparing four treatment strategies Blackwell Science Ltd Aim : To compare the efficacy of different regimens in patients in whom previous Helicobacter pylori eradication therapy has failed.Methods : In this study named StratHegy patients (n = 287) were randomized to receive one of three empirical triple therapy regimens or a strategy based on antibiotic susceptibility. The empirical regimens were omeprazole, 20 mg b.d., plus amoxicillin, 1000 mg b.d., and clarithromycin, 500 mg b.d., for 7 days (OAC7), clarithromycin, 500 mg b.d., for 14 days (OAC14) or metronidazole, 500 mg b.d., for 14 days (OAM14). In the susceptibility-based strategy, patients with clarithromycin-susceptible strains received OAC14, whilst the others received OAM14. The 13C-urea breath test was performed before randomization and 4–5 weeks after eradication therapy.Results : In the intention-to-treat analysis, the eradication rates for empirical therapies were as follows: OAC7, 47.4% (27/57); OAC14, 34.5% (20/58); OAM14, 63.2% (36/57); it was 74.3% (84/113) for the susceptibility-based treatment (P 〈 0.01 when compared with OAC7 and OAC14). In patients receiving clarithromycin, the eradication rates were 80% for clarithromycin-susceptible strains and 16% for clarithromycin-resistant strains; in patients receiving OAM14, the eradication rates were 81% for metronidazole-susceptible strains and 59% for metronidazole-resistant strains.Conclusions : Eradication rates of approximately 75% can be achieved with second-line triple therapy based on antibiotic susceptibility testing. If susceptibility testing is not available, OAM14 is an appropriate alternative. 1365-2036 13652036 |
| shingle_catch_all_4 | Lamouliatte, H. Mégraud, F. Delchier, J.-C. Bretagne, J.-F. Courillon-Mallet, A. De Korwin, J.-D. Fauchère, J.-L. Labigne, A. Fléjou, J.-F. Barthelemy, P. Second-line treatment for failure to eradicate Helicobacter pylori: a randomized trial comparing four treatment strategies Blackwell Science Ltd Aim : To compare the efficacy of different regimens in patients in whom previous Helicobacter pylori eradication therapy has failed.Methods : In this study named StratHegy patients (n = 287) were randomized to receive one of three empirical triple therapy regimens or a strategy based on antibiotic susceptibility. The empirical regimens were omeprazole, 20 mg b.d., plus amoxicillin, 1000 mg b.d., and clarithromycin, 500 mg b.d., for 7 days (OAC7), clarithromycin, 500 mg b.d., for 14 days (OAC14) or metronidazole, 500 mg b.d., for 14 days (OAM14). In the susceptibility-based strategy, patients with clarithromycin-susceptible strains received OAC14, whilst the others received OAM14. The 13C-urea breath test was performed before randomization and 4–5 weeks after eradication therapy.Results : In the intention-to-treat analysis, the eradication rates for empirical therapies were as follows: OAC7, 47.4% (27/57); OAC14, 34.5% (20/58); OAM14, 63.2% (36/57); it was 74.3% (84/113) for the susceptibility-based treatment (P 〈 0.01 when compared with OAC7 and OAC14). In patients receiving clarithromycin, the eradication rates were 80% for clarithromycin-susceptible strains and 16% for clarithromycin-resistant strains; in patients receiving OAM14, the eradication rates were 81% for metronidazole-susceptible strains and 59% for metronidazole-resistant strains.Conclusions : Eradication rates of approximately 75% can be achieved with second-line triple therapy based on antibiotic susceptibility testing. If susceptibility testing is not available, OAM14 is an appropriate alternative. 1365-2036 13652036 |
| shingle_title_1 | Second-line treatment for failure to eradicate Helicobacter pylori: a randomized trial comparing four treatment strategies |
| shingle_title_2 | Second-line treatment for failure to eradicate Helicobacter pylori: a randomized trial comparing four treatment strategies |
| shingle_title_3 | Second-line treatment for failure to eradicate Helicobacter pylori: a randomized trial comparing four treatment strategies |
| shingle_title_4 | Second-line treatment for failure to eradicate Helicobacter pylori: a randomized trial comparing four treatment strategies |
| sigel_instance_filter | dkfz geomar wilbert ipn albert |
| source_archive | Blackwell Publishing Journal Backfiles 1879-2005 |
| timestamp | 2024-05-06T08:10:56.559Z |
| titel | Second-line treatment for failure to eradicate Helicobacter pylori: a randomized trial comparing four treatment strategies |
| titel_suche | Second-line treatment for failure to eradicate Helicobacter pylori: a randomized trial comparing four treatment strategies |
| topic | WW-YZ |
| uid | nat_lic_papers_NLZ242200826 |